Announcement of an article in the Nikkei Biotech ONLINE

Our company is considering expanding its PAI-1 inhibitor RS5614 into the anti-aging and longevity fields, in addition to its use as a prescription drug for human cancer and other conditions. The anti-aging and longevity effects of RS5614 are expected to be useful not only in human medicine, but also in veterinary medicine, primarily for companion animals¹⁾ such as dogs and cats. Therefore, we have begun research into veterinary medicine for dogs and cats (disclosed on February 4, 2026).

We are pleased to announce that the background to our efforts and specific business in veterinary medicine were featured in a Nikkei Biotech ONLINE news article dated March 6, 2026.

Nikkei Biotech ONLINE article
https://bio.nikkeibp.co.jp/atcl/news/p1/26/02/26/14295/

1）Companion Animals
This refers to animals, primarily dogs and cats, kept at home and living with humans. More than just pets, they are often treated as family members, and in recent years, with the aging population, demand for them in the medical and healthcare fields has expanded significantly.